{"url_path":"/sec/fate/8-k/2026-06-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-271055-index.html","accession_number":"0001193125-26-271055","cik":"0001434316","ticker":"FATE","issuer_name":"FATE THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-271055-index.html","primary_entity_key":"0001434316","primary_entity_name":"FATE THERAPEUTICS INC"},"word_count":124,"has_tables":true,"body_markdown":"## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAs described below in Item 5.07 of this Current Report on Form 8-K, on June 12, 2026, the stockholders of Fate Therapeutics, Inc. (the “Company”) approved a third amendment and restatement of the Company’s 2022 Stock Option and Incentive Plan (as so amended and restated, the “2022 A&R Plan”) to increase the maximum number of shares available under such plan by an additional 7,000,000 shares. A copy of the 2022 A&R Plan, including the form of award agreements under the 2022 A&R Plan, is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated in this Item 5.02 by reference."}